Zymeworks Announces Five Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021
Zymeworks Inc. (NYSE: ZYME) announced five abstracts for poster presentations at the AACR Annual Meeting 2021, taking place virtually from April 10-15, 2021. Highlights include presentations on the PROTECT™ antibody platform, tumor-specific IL-12 engineering, insights into bispecific antibodies, and the bispecific antibody zanidatamab's mechanisms and anti-tumor activity in HER2 cancers. Zymeworks is advancing its lead candidate, zanidatamab, in pivotal clinical trials for refractory HER2-amplified biliary tract cancer and other HER2-expressing cancers.
- Acceptance of five abstracts for presentation at a major cancer conference.
- Lead candidate zanidatamab has received Breakthrough Therapy designation from the FDA.
- Ongoing pivotal trials for zanidatamab in refractory HER2-amplified cancers and Phase 2 trials for HER2-expressing cancers.
- None.
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the acceptance of five abstracts for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2021 taking place virtually from April 10 – 15, 2021.
The poster presentations will be available on Saturday, April 10 at 8:30 am ET on the conference website as well as the Zymeworks website.
Presentation Details
Title: PROTECT™, a novel antibody platform for integrating tumor-specific immune modulation and enhancing the therapeutic window of targeted multispecific biologics
Abstract: 924
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibody Technologies
Title: Increasing the therapeutic index of IL-12 by engineering for tumor-specific protease activation
Abstract: 1788
Session Category: Immunology
Session Title: Modifiers of the Tumor Microenvironment
Title: Understanding the geometry and valency of bispecific antibodies in the optimization of tumor-dependent activation of 4-1BB
Abstract: 1737
Session Category: Immunology
Session Title: Immunomodulatory Agents and Interventions
Title: Super-resolution imaging studies of zanidatamab: providing insights into its bispecific mode of action
Abstract: 1032
Session Category: Experimental and Molecular Therapeutics
Session Title: Cellular Responses to Anticancer Drugs
Title: The bispecific antibody zanidatamab’s (ZW25’s) unique mechanisms of action and durable anti-tumor activity in HER2-expressing cancers
Abstract: 1005
Session Category: Experimental and Molecular Therapeutics
Session Title: Cellular Responses to Anticancer Drugs
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric™ bispecific antibody which has been granted Breakthrough Therapy designation by the FDA and is currently enrolling in a pivotal clinical trial for refractory HER2-amplified biliary tract cancer (HERIZON-BTC-01) as well as several Phase 2 clinical trials for HER2-expressing gastroesophageal and breast cancers. Zymeworks’ second clinical candidate, ZW49, is a novel bispecific HER2-targeting antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies. For additional information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.
Cautionary Note Regarding Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements in this news release include, but are not limited to, statements that relate to Zymeworks’ clinical and preclinical development of its product candidates, related clinical trials, and other information that is not historical information. When used herein, words such as “will”, “may”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation, market conditions and the factors described under “Risk Factors” in Zymeworks’ Annual Report on Form 10-K for its fiscal year ended December 31, 2020 (a copy of which may be obtained at www.sec.gov and www.sedar.com). Consequently, forward-looking statements should be regarded solely as Zymeworks’ current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Zymeworks cannot guarantee future results, events, levels of activity, performance or achievements. Zymeworks does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005992/en/
FAQ
What are the key highlights from Zymeworks' recent press release?
What is zanidatamab and what trials is it undergoing?
When will the AACR Annual Meeting 2021 take place?
What is the significance of the Breakthrough Therapy designation for zanidatamab?
How can I access Zymeworks' poster presentations during the AACR meeting?
